Next-Generation TKI Approved for Advanced ROS1-Positive Lung Cancer

(MedPage Today) — The FDA approved taletrectinib (Ibtrozi) — a next-generation oral ROS1 tyrosine kinase inhibitor (TKI) — for the treatment of adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC)…

Source link : https://www.medpagetoday.com/hematologyoncology/lungcancer/116021

Author :

Publish date : 2025-06-11 20:19:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30

Next-Generation TKI Approved for Advanced ROS1-Positive Lung Cancer

Tulane Scientist Resigns, Cites Censorship of Pollution and Disparities Research

Oncology Community Rallies, Rails Against ‘Draconian’ Budget Cuts for NIH, NCI

Related Posts

Governors of Washington, Oregon, and California Form a Health Alliance

State Plans to End School Vax Mandates, First to Do So

Lupus, RA Hit Pregnant Veterans Hard

Not Sure Where to Turn for Trusted Vaccine Guidance?

3D-printing could make it easier to make large quantum computers

U.S. Media Quickly Forced to Revisit How a President’s Health Should Be Covered

Governors of Washington, Oregon, and California Form a Health Alliance

State Plans to End School Vax Mandates, First to Do So

Lupus, RA Hit Pregnant Veterans Hard

Not Sure Where to Turn for Trusted Vaccine Guidance?

3D-printing could make it easier to make large quantum computers

U.S. Media Quickly Forced to Revisit How a President’s Health Should Be Covered

CDC Resignations: These Are the Lines That Were Crossed

Staff called ‘heartless’ over Nottingham maternity review remarks

Categories

Archives